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Abstract
Sex-related differences have been noted in cardiovascular anatomy, pathophysiology, and
treatment responses, yet we continued to drive evaluation of vascular device development
in animal models without consideration of animal sex. We aimed to understand sex-related
differences in the vascular responses to stent implantation by analyzing the pooled data of
endovascular interventions in 164 Yucatan mini-swine (87 female, 77 male). Bare metal
stents (BMS) or drug-eluting stents (DES) were implanted in 212 coronary arteries (63 sin-
gle BMS implantation, 68 single DES implantation, 33 overlapped BMS implantation, and 48
overlapped DES implantation). Histomorphological parameters were evaluated from vascu-
lar specimens at 3–365 days after stent implantation and evaluated values were compared
between female and male groups. While neointima formation at all times after implantation
was invariant to sex, statistically significant differences between female and male groups
were observed in injury, inflammation, adventitial fibrosis, and neointimal fibrin deposition.
These differences were observed independently, i.e., for different procedure types and at
different follow-up timings. Only subtle temporal sex-related differences were observed in
extent and timing of resolution of inflammation and fibrin clearance. These subtle sex-
related differences may be increasingly important as interventional devices meld novel
materials that erode and innovations in drug delivery. Erodible materials may act differently
if inflammation has a different temporal sequence with sex, and drug distribution after bal-
loon or stent delivery might be different if the fibrin clearance speaks to different modes of
pharmacokinetics in male and female swine.
Introduction
Cardiovascular disease (CVD) is the main cause of death in women and men around the
world [1]. However, like most diseases, its diagnostic criteria and treatments protocols have
been developed from studies dominated by enrollment with male patients. In 2001, the Insti-
tute of Medicine declared that: “sex differences should be considered in all health-related
research, research should concentrate on sex-differences in diagnosis and treatment, and on
the mechanisms and therapies related to sex differences, and obstacles to advance sex-related
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research in health and illness must be eliminated” [2]. A large amount of research has identi-
fied sex differences that may affect the symptoms and therapeutic outcomes of CVD, such as
anatomic and physiologic differences. Arterial diameters and wall thickness are thinner in
women than in men [3–5], and left atrial and ventricular end-diastolic dimensions are differ-
ent [6]. The basic pathology of arterial disease is indeed different between men and women.
Necrotic lesions are more evident in women, while men demonstrate more calcified, fibrous,
and fibrofatty plaques [7, 8]. It can therefore be understood why plaque erosion with acute
thrombosis was observed more in women than in men (men: 18.5%, women: 37.4%), and rup-
ture more frequently in men (men: 76%, women: 55%) [9, 10]. The onset of CVD is about 10
years later in women than in men [8, 11].
Concern has been raised that these differences might herald sex-related difference in thera-
peutic outcomes. Drug therapies for atherosclerosis and CVD have made great advances, but
women have not derived as much benefit as men. Women tend to experience more drug-
related adverse events than men, perhaps from differences in body mass, volume of drug dis-
tribution, liver metabolism, and/or kidney function [8]. Some clinical trials for drugs, includ-
ing those for aspirin, the most prevalent drug used for CVD, have addressed this disparity
[11]. Although a meta-analysis of primary prevention studies did not suggest sex differences in
the response to aspirin, differences were evident in secondary studies, which showed that a
first stroke, but not a first heart attack, is prevented with a low dose of aspirin in women, and
that the reverse is true in men (i.e., a first heart attack but not a first stroke is prevented) [11].
The cause of the difference in the effect of aspirin has not yet been delineated [12], but this dif-
ference has been attributed to differences in platelet biology, including especially higher base-
line platelet reactivity in response to agonists in women than in men has been reported [13].
The efficacy of statins also demonstrates sex-related differences. Secondary prevention trials
show that statins seem to work equally in women and men with established CVD; however, in
the recent large primary prevention trial, more robust reduction in cardiac event with statin
therapy was observed in women than in men without an evident CVD risk [11].
In addition, sex-related differences in the outcomes of stent implantation have been studied
[14–43]; however, the results are controversial for bare metal stent (BMS) and drug-eluting
stent (DES) implantation. For example in BMS implantation, Mehilli et al. demonstrated
higher rates of death, non-fatal myocardial infarction, and urgent target vessel revasculariza-
tion in women than in men within 30 days after the implantation, and lower rates of clinical
restenosis rate and target vessel revascularization in women than in men at 1-year follow-up
[42]. On the other hand, Lansky et al. demonstrated no sex-related difference between women
and men at any follow-up timing [38]. Little research focuses on sex-related differences in the
outcomes of DES implantation. One study demonstrated that no sex-related differences were
observed in the outcomes of Sirolimus-eluting stent implantation after adjusting for the sex-
related differences in confounding variables [33, 36]. Another study showed that women
undergoing Zotarolimus-eluting stent implantation tend to have higher in-stent and in-seg-
ment percent diameter restenosis and lower rates of revascularization, but have similar rates of
death and myocardial infarction compared to men [44]. The difference between these two
studies were attributed to drugs differences: Sirolimus might induce more thrombotic events
due to inflammation response, while Zotarolimus reduces thrombotic events [25], or sex-
related difference in platelet biology. However, in all of these clinical trials, the percentages of
women were about 20–30% and women tended to be older and have more risks of CVD than
men. This difference may induce the ambiguous results in clinical trials and prevent us from
understanding the purely sex-related differences in the outcomes of stent implantation.
The National Institutes of Health now use consideration of sex as a biological variable as a
dominant criterion in evaluation of research funding proposals and yet sex has rarely been
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evaluated in animal model systems. These systems are an essential bedrock of research into
vascular biology and in the determination of the safety/efficacy of endovascular interventions.
Animal systems are ideal for testing specific hypotheses that drive vascular disease and much
of what we know of vascular biology is derived from animal work. Endovascular therapies
require evaluation in animal systems before clinical evaluation can commence. Yet, few if any
studies are concerned with the choice of sex in preclinical studies. It is for this reason that we
pooled data from extensive experience in preclinical studies to determine if sex-related differ-
ences could be identified in the vascular responses to the stent implantation.
Materials and methods
Animal study population
All animal studies were performed at GLP AAALAC accredited animal facility (CBSET, Inc.,
Lexington, MA) and adhered to the Guide for the Care and Use of Laboratory Animals under
an Institutional Animal Care and Use committee-approved protocol. We pooled data from
164 Yucatan mini-swine (4-month old). Among all mini-swine, 87 (53%) were nulliparous
female and 77 (47%) were castrated male. BMS or DES was implanted in the three main coro-
nary arteries with standard procedure. The procedure is described in S1 Appendix. Within 212
stented vessels in total, 63 (29.7%) were single-usage of BMS, 68 (32.1%) were single-usage of
DES, 33 (15.6%) were overlapped-usage of BMS, and 48 (22.6%) were overlapped-usage of
DES (Table 1). The baseline diameter and post-implant diameter are summarized in Table 2.
Histological specimens were taken from proximal, middle, and distal regions of each stent-
implanted vessel at different times (3, 30, 90, 180, and 365 days) after stent implantation. From
each histology specimen, neointima area (AN) and lumen area (AL) were measured, and lumi-
nal occlusion (OL) was calculated as follows: OL = AN/(AN+AL). Histomorphological parame-
ters, i.e., injury score, inflammation score, adventitial fibrosis score, neointimal fibrin score,
neointimal maturation score, and endothelialization score, were also evaluated from each spec-
imen (Table 3). All the evaluations were performed at CBSET, Inc., and its process is described
in S2 Appendix.
Statistical analysis
After dividing the data into female and male groups, the data was subcategorized based on the
stent type (BMS or DES), the single- or overlapped-usage, and the follow-up timing. We could
not subcategorize the data based on the artery and its region (proximal, middle, or distal)
because of the limited sample size. Average and standard deviation (SD) were calculated for all
evaluated values in each subcategorized group. The statistical significance between female and
male groups was evaluated in each subcategorized group by applying Student’s t-test.
Table 1. Summary of available animal data.
Time point All mini-swine Male mini-swine Female mini-swine
Single Overlap Single Overlap Single Overlap
BMS DES BMS DES BMS DES BMS DES BMS DES BMS DES
Day 3 8 18 8 8 2 8 2 3 6 10 6 5
Day 30 18 27 8 20 12 15 4 9 6 12 4 11
Day 90 20 23 9 20 12 10 6 11 8 13 3 9
Day 180 9 0 8 0 4 0 5 0 5 0 3 0
Day 365 8 0 0 0 3 0 0 0 5 0 0 0
Totals 63 68 33 48 33 33 17 23 30 35 16 25
https://doi.org/10.1371/journal.pone.0192004.t001
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Results
Neointima area and luminal occlusion
Though mean neointima area did not reach statistically significant differences between female
and male mini-swine under any procedure protocols at any time after implantation (Figs 1
Table 2. Summary of baseline diameter and post-implant diameter.
Baseline diameter
Procedure type Follow-up day Male [mm] Female [mm] p-value
BMS single Day 3 2.73 2.86 ± 0.24 0.498
Day 30 2.78 ± 0.15 2.69 ± 0.11 0.224
Day 90 2.71 ± 0.15 2.73 ± 0.14 0.729
Day 180 2.75 ± 0.09 2.70 ± 0.13 0.402
Day 365 2.86 ± 0.17 2.83 ± 0.10 0.717
BMS overlap Day 3 2.75 2.88 ± 0.17 0.362
Day 30 2.71 ± 0.08 2.70 ± 0.07 0.892
Day 90 2.77 ± 0.05 2.90 ± 0.01 0.001
Day 180 2.65 ± 0.08 2.85 ± 0.02 0.006
DES single Day 3 2.79 ± 0.11 2.74 ± 0.15 0.354
Day 30 2.79 ± 0.17 2.74 ± 0.17 0.509
Day 90 2.67 ± 0.14 2.74 ± 0.15 0.321
Day 180 2.73 ± 0.12 2.78 ± 0.13 0.374
Day 365 2.89 ± 0.13 2.77 ± 0.20 0.292
DES overlap Day 3 2.77 ± 0.19 2.97 ± 0.09 0.086
Day 30 2.77 ± 0.11 2.78 ± 0.15 0.924
Day 90 2.79 ± 0.09 2.80 ± 0.16 0.895
Day 180 2.88 ± 0.11 2.76 ± 0.15 0.091
Post-implant diameter
Procedure type Follow-up day Male [mm] Female [mm] p-value
BMS single Day 3 2.97 3.09 ± 0.20 0.454
Day 30 2.90 ± 0.23 2.83 ± 0.26 0.588
Day 90 2.90 ± 0.18 2.95 ± 0.21 0.629
Day 180 2.89 ± 0.13 2.87 ± 0.18 0.782
Day 365 3.02 ± 0.29 3.03 ± 0.10 0.955
BMS overlap Day 3 2.84 3.08 ± 0.24 0.229
Day 30 2.94 ± 0.14 2.97 ± 0.10 0.773
Day 90 3.01 ± 0.12 3.10 ± 0.07 0.207
Day 180 2.93 ± 0.08 3.08 ± 0.03 0.021
DES single Day 3 2.94 ± 0.27 2.91 ± 0.17 0.747
Day 30 2.92 ± 0.20 2.95 ± 0.27 0.806
Day 90 2.91 ± 0.19 2.88 ± 0.19 0.765
Day 180 3.03 ± 0.18 3.03 ± 0.13 0.987
Day 365 3.09 ± 0.15 2.93 ± 0.20 0.222
DES overlap Day 3 2.88 ± 0.09 3.13 ± 0.08 0.007
Day 30 3.03 ± 0.20 3.04 ± 0.20 0.967
Day 90 3.07 ± 0.14 3.02 ± 0.19 0.538
Day 180 3.17 ± 0.15 3.04 ± 0.25 0.260
All the values are evaluated as average ± standard deviation. If the number of data is smaller than 3, only average is evaluated.
The mark ‘’ shows at which procedure type and follow-up timing a statistically significant difference was observed between male and female groups.
https://doi.org/10.1371/journal.pone.0192004.t002
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and 2), there was a subtle difference in the timing of vascular recovery. Higher luminal occlu-
sion with statistically significant differences was observed 30 days after overlapped BMS
implantation in the male group, 365 days after single DES implantation in the female group,
and 180 days after overlapped DES implantation in the female group (Fig 3). However, no sig-
nificant difference between female and male groups was observed in the distribution of lumi-
nal occlusion at any follow-up time under any procedure protocols (Fig 4).
Injury and inflammation
Similarly, though vascular injury was minimal (injury scores less than 1) for both sexes, injury
was more statistically persistent and elevated at later times in the females; 180 days after single
Table 3. Scoring scheme for histomorphological parameters.
0 1 2 3 4
Injury No injury;
internal elastic
lamina intact
Disruption of internal
elastic lamina
Disruption of tunica media Disruption of external elastic lamina/
tunica adventitia
N/A
Inflammation No cells present < 20 cells associated
with stent strut
> 20 cells associated with stent strut;
with or without tissue effacement; little
to no impact on tissue function
> 20 cells associated with stent strut;
adjacent vascular tissue effacement;
adverse impact on tissue function
N/A
Neointimal fibrin Absent Infrequent spotting of
fibrin
Heavier deposition of fibrin Heavy deposition of fibrin spanning
between struts
N/A
Neointimal
maturation
Absent Immature,
predominantly fibrino-
vascular tissue
Transitional, predominantly organizing
smooth muscle
Mature, generalized organized smooth
muscle
N/A
Adventitial fibrosis Absent Minimal presence of
fibrous tissue
Notable fibrous tissue in 25–50% of
artery circumference
Notable fibrous tissue in > 50% of
artery circumference
N/A
Endothelialization Absent < 25% 25–75% > 75% 100%,
confluence
Injury and inflammation scores were assessed on a per strut basis, and the average of these strut scores represent the aggregate planar score. All other parameters were
planar scores.
https://doi.org/10.1371/journal.pone.0192004.t003
Fig 1. Neointima area at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation,
(C) Single DES implantation, (D) Overlapped DES implantation. No significant differences between female and male
groups were observed at any following timings.
https://doi.org/10.1371/journal.pone.0192004.g001
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BMS implantation, 365 days after single DES implantation, and 180 days after overlapped DES
implantation (Fig 5). Perhaps, as a consequence, there were higher adventitial fibrosis scores with
statistical significance at these later times in the female group and earlier in the male group (Fig
6). Inflammation was limited and only higher in males 365 days after single BMS implantation,
but no statistically significant differences were observed in other conditions (Fig 7). For all follow-
up timings and for all procedures, neointimal maturation and endothelialization were complete.
Neointimal fibrin score
Neointimal fibrin is a maker of drug delivery as it correlates with vascular fragility from local
drug depots. Statistically higher neointimal fibrin scores were observed in male swine arteries
Fig 2. Distribution of neointima area. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single
DES implantation, (D) Overlapped DES implantation. No significant differences between female and male groups
were observed.
https://doi.org/10.1371/journal.pone.0192004.g002
Fig 3. Luminal occlusion at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation,
(C) Single DES implantation, (D) Overlapped DES implantation. Higher luminal occlusion with statistically significant
difference were observed 30 days after overlapped BMS implantation in the male group (B), 365 days after single DES
implantation in the female group (C), and 180 days after overlapped DES implantation (D).
https://doi.org/10.1371/journal.pone.0192004.g003
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with DES 30 and 180 days after single and 90 days after overlapped implantation (Fig 8). Fibrin
scores decreased significantly more rapidly in the female swine as well.
Discussions
Sex differences in vascular responses to catheter-based intervention have been sought with just
cause. Several studies observed the sex-related difference in onset of cardiovascular events [8,
11], which has induced an on-going debate with regard to the role of sex hormones in cardio-
vascular disease [11, 45]. Women tend to bleed more during and after vascular procedures
than men do and women are more prone to clotting due to higher baseline platelet activity
Fig 4. Distribution of luminal occlusion. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single
DES implantation, (D) Overlapped DES implantation. No significant differences between female and male groups
were observed.
https://doi.org/10.1371/journal.pone.0192004.g004
Fig 5. Injury score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C)
Single DES implantation, (D) Overlapped DES implantation. Higher injury scores were observed in the female group
180 days after single BMS implantation (A), 365 days after single DES implantation (C), and 180 days after overlapped
DES implantation (D).
https://doi.org/10.1371/journal.pone.0192004.g005
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than men [5]. However, the sex-related differences in outcomes of intervention have not been
understood clinically because it is hard to balance sexes in the clinical trials. The National
Institute of Health (NIH) has encouraged the scientific community to improve the balance in
research [46], and all NIH grants must now document the consideration of sex as a biological
variable. Given the control over conditions that are so inherently variable clinically like envi-
ronment and tissue state and dimensions the preclinical domain is an excellent venue to exam-
ine sex-dependent issues [47]. Yet, few if any have looked at whether sex plays a role in the
response to endovascular implantation in classic animal models. Coronary arteries of domestic
Fig 6. Adventitial fibrosis score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS
implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Higher adventitial fibrosis scores were
observed 180 days after single BMS implantation in the female group (A), 365 days after single BMS implantation in
the male group (A), 30 days after overlapped BMS implantation in the male group (B), 30 and 90 days after single DES
implantation in the male group (C), and 365 days after single DES implantation in the female group (C).
https://doi.org/10.1371/journal.pone.0192004.g006
Fig 7. Inflammation score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS
implantation, (C) Single DES implantation, (D) Overlapped DES implantation. A higher inflammation score with
statistical significance was observed in the male group 365 days after single BMS implantation (A).
https://doi.org/10.1371/journal.pone.0192004.g007
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crossbred or mini-swine, or rabbit iliac arteries are considered as the classic animal models for
human vascular diseases [48], and FDA approval requires examination of devices, including
BMS and DES, in swine models. Despite requiring that sex should be considered in research,
we still have never formally examined whether animals should be balanced for sex or whether
this issue is moot. To the best of our knowledge, this study attempted for the first time to reveal
sex-related differences in outcomes of stent implantation in preclinical setting.
We pooled data from an extensive database of studies with stents and looked across a wide
array of histomorphometric responses segregated by sex. While there were no major sex-related
differences in neointima formation as the primary determinant of vascular repair in any of stent
implantation procedures, there were statistically significant differences on a variety of parame-
ters that might well emerge as important in specific instances. For example, injury and inflam-
mation persisted for longer in the female swine and adventitial fibrosis and neointimal fibrin
deposition were greater in in the males, which is consistent with the clinical trial results.
We need though to careful contextualize our findings since we seek not to recapitulate the
human condition in the animal or even to answer whether vascular interventions are different
in women and men but rather to understand if the biology in animals is sex-dependent.
Accordingly let us first comment on what it means to be a male and female animal, second to
understand if any confounding variables like arterial dimensions or device type could have
biased the results, and then to understand the biologic consequences of variations in compo-
nent parts of the repair pathways and final lesion formed.
Sex in an animal
Animals are not humans and indeed animal models are used to investigate mechanisms and
hypotheses not to predict responses in people. Animals in experimental model departs from
Fig 8. Neointimal fibrin score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS
implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Black lines in the male group at 90,
180, and 365 days after single BMS implantation and at 365 days after single DES implantation, and in the female
group at 90 days after single BMS implantation, at 90 days after overlapped BMS implantation, and at 365 days after
single DES implantation indicate that the neointimal fibrin scores were 0. A higher neointimal fibrin score was
observed in male group 30 and 180 days after single DES implantation (C), and 90 days after overlapped DES
implantation (D). The statistically significant decreases over time were observed in the female group after single and
overlapped DES implantation (C, D).
https://doi.org/10.1371/journal.pone.0192004.g008
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the humans in clinical trials. Aside from the obvious age difference and environmental expo-
sures, the notions of sex are different in experimental models and trial subjects. Almost all the
animals used in this study are 4 months old and are often raised on carefully controlled chow
in carefully modulated and monitored environments. There is no hypertension or diabetes
mellitus unless introduced artificially, or there is no tobacco abuse or “unhealthy” lifestyle.
More importantly for us, femaleness and maleness have different insinuations. Male animals
in experimental systems are most often neutered and female swine most often pre-menarchal
placing animals on the different extreme of the natural spectrum of sex hormonal exposure
than older human subjects. Although the mini-swine reproductive system is similar to that of
human, mini-swine are sexually matured at 5–6 months old, while these animals are usually 4
months old at the initiation of preclinical studies. In addition, these studies mostly follow up to
12 months, when sexual maturation begins. As studies go longer and longer, especially when
we begin to examine stents with erodible coatings or backbones, the sexual maturation may
overlap with follow-up and we may understand the influence of sex on the outcomes. Thus,
our data are valuable to scientists especially in an era where federal mandates to consider sex
as a biological variable are ubiquitous but we are careful not to claim association with the
human condition.
Confounding variables in preclinical trials
Preclinical experiments are carefully mandated and especially as all the experiments repre-
sented here were performed not only in an AAALAC-accredited facility but under GLP guid-
ance as well. Sex-related difference in clinical outcomes of stent implantation may well have
arisen from anatomic differences between women and men as arterial dimensions are smaller
in women than in men [3–5]. This was not the case in our pooled animal data. There was no
statistically significant difference in baseline arterial diameter or post-implant diameter
between male and female swine in 16 out of 18 different device type and follow-up timing
group. In the other 2 groups, in which statistically significant difference was observed, the
diameters were minimally greater in the female not the male swine (Table 2). This lack of dif-
ference in dimensions is of no surprise given that preclinical protocols careful dictate ranges of
diameters and given that dimensions are critical in the animal anatomic identity is essential.
Such matching strengthens the arguments of these findings.
Different hemodynamic patterns could potentially influence the outcomes of stent implan-
tation. In the pooled data, the stents were implanted in all three coronary arteries and we and
others have shown differential physical forces and hemodynamic patterns on the different cor-
onary arteries [49]. Although statistical analysis could not be performed by subcategorizing
our analysis by each coronary artery due to the limited sample size, no difference was observed
in neointima area, restenosis rate, or any histomorphological parameters among three coro-
nary arteries. Single-usage or overlapped-usage also create different hemodynamic pattern and
net effects were identical to single stenting.
Component pathways and cumulative biologic effect
One important element from this work is that overall cumulative effects on an artery like ulti-
mate neointimal hyperplasia and thrombosis are no different in female and male swine though
different pathways and elements of the response to injury do show differential effects. This is
an important finding and not contradictory. Neointima or clot formation are the end result of
a multitude of processes and are subject to the full range of biologic, biochemical, physical and
hemodynamic effects. The metrics integrate all of the net biologic effects that confront the
artery, and it is impossible to predict the end result from isolated component parts. This may
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well explain why effects like fibrin deposition cannot predict overall thrombosis, or inflamma-
tion and proliferation cannot predict ultimate neointimal mass. Cumulative effects integrate
many events such as arterial geometry and flow as well as physiology and biology and it is
essential that these two sets of effects are reported independently and precisely.
That differences in specific biological pathways after stent implantation bare metal and
drug-eluting, with regard to sex is important in helping investigators plan and justify future
studies. This is especially the case as subtle sex-related differences may be of increasing impor-
tance as interventional devices meld novel materials that erode and innovations in drug deliv-
ery. Erodible materials may act differently if inflammation has a different temporal sequence
with sex, and drug distribution after balloon or stent delivery might be different if the fibrin
clearance speaks to different modes of pharmacokinetics in male and female swine.
Conclusions
In this study, we used a pooled data of catheter-based interventions in more than 200 coronary
arteries of Yucatan mini-swine to understand sex-related influence on vascular repair after
stent implantation. Animals were split almost equally between males and females and both
bare metal and drug eluting stents were considered in single and overlapped configurations.
While several clinical studies observed sex-related differences in cardiovascular events, our
pooled data showed no sex-related differences in the major bulk properties of thrombosis,
neointima formation or luminal occlusion at all times in follow-up from 1 month to 1 year
after stent implantation. Statistically significant differences between male and female swine
were observed in histomorphological parameters directed at resolution of fibrin deposition
after drug delivery and degree of inflammation. These issues speak to the mandate to consider
sex as a biological variable in animal experiments and will likely become important when we
consider complex convergence technologies such as erodible materials where the dynamics of
vascular repair after initial events determine late effects.
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